Compare LKFN & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | TYRA |
|---|---|---|
| Founded | 1872 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 1997 | 2021 |
| Metric | LKFN | TYRA |
|---|---|---|
| Price | $60.30 | $23.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $67.00 | $32.17 |
| AVG Volume (30 Days) | 157.8K | ★ 576.3K |
| Earning Date | 01-23-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.79 | N/A |
| Revenue | ★ $248,271,000.00 | N/A |
| Revenue This Year | $17.16 | N/A |
| Revenue Next Year | $3.98 | N/A |
| P/E Ratio | $15.81 | ★ N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $50.00 | $6.42 |
| 52 Week High | $73.85 | $24.05 |
| Indicator | LKFN | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 57.46 | 68.10 |
| Support Level | $59.00 | $21.65 |
| Resistance Level | $60.56 | $23.74 |
| Average True Range (ATR) | 1.33 | 1.29 |
| MACD | 0.27 | -0.12 |
| Stochastic Oscillator | 87.73 | 72.96 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.